scholarly journals Optimization of the Inclusion of Alzheimer's Disease Patients in International Multicenter Randomized Trials: Results of a National Survey Conducted in Memory Research Centers in France

2013 ◽  
Vol 3 (1) ◽  
pp. 417-425 ◽  
Author(s):  
A.E. Tchalla ◽  
C. Adam ◽  
C. Gayot ◽  
P. Cowppli-Bony ◽  
P.M. Preux ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
National Survey ◽  
Randomized Trials ◽  
Research Centers ◽  
Memory Research ◽  
International Multicenter

A-19 The Effect of Type 2 Diabetes on Attention and Executive Functioning in Mild Cognitive Impairment Patients

2021 ◽  
Vol 36 (6) ◽  
pp. 1060-1060
Author(s):  
Zachary Peart ◽  
Samantha Spagna ◽  
Bailey McDonald ◽  
Brittny Arias ◽  
D'anna Sydow ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Type 2 Diabetes ◽  
Alzheimer's Disease ◽  
Executive Functioning ◽  
Digit Span ◽  
Research Centers ◽  
Disease Research ◽  
Altered Glucose ◽  
Increased Risk

Abstract Objective To investigate the effects of Type 2 Diabetes (T2D) on performance on attention and executive function measures in a sample of MCI patients. Method Individuals with a clinician diagnosis of MCI with T2D and [n = 719,Mage = 75.24,50.3% female] and MCI persons without T2D [n = 719,Mage = 75.21,47.1% female] were selected from the Alzheimer’s Disease Research Centers database by the National Institute on Aging. Those with motor disturbances were excluded from the analysis. Significant differences (p < 0.001) were found for race and education between groups. Results Multiple ANCOVAs controlled for gender, education, age, and race on performance. Significant differences (p < 0.001) were found in performance on the Trail Making Test [A, B], Digit Span forward [longest recall, correct trials], Digit Span backward [longest recall, correct trials], and Verbal Fluency tasks [F word, L words]. No significant differences were found in the animal and vegetable naming fluency tasks. The T2D group showed poorer mean scores on every test analyzed. Conclusion Results indicated modestly lower performance on measures of attention and executive functioning in MCI patients with comorbid T2D. Previous research supports these conclusions, as T2D has been associated with increased risk for dementia, accelerated decline from MCI to dementia, and modestly lower scores on cognitive tests via effects of microvascular function and altered glucose metabolism. Future studies should aim to identify protective factors in T2D cognitive decrements while controlling for exercise, diet, SES, and underlying medical comorbidities. The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded Alzheimer’s Disease Research Centers.

Clinical and Bacterial Markers of Periodontitis and Their Association with Incident All-Cause and Alzheimer’s Disease Dementia in a Large National Survey

2020 ◽  
Vol 75 (1) ◽  
pp. 157-172 ◽  
Author(s):  
May A. Beydoun ◽  
Hind A. Beydoun ◽  
Sharmin Hossain ◽  
Ziad W. El-Hajj ◽  
Jordan Weiss ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
National Survey ◽  
Alzheimer’S Disease Dementia

scholarly journals Nootropic drugs for correction of cognitive functions through the focus of evidence-based medicine (literature review)

2021 ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Literature Review ◽  
Cognitive Functions ◽  
Evidence Based Medicine ◽  
Randomized Trials ◽  
Evidence Based ◽  
Nootropic Drugs ◽  
High Quality ◽  
Based Medicine

Relevance. In today's world, the first cause of death is pathology of the cardiovascular system. Vascular disease is influenced by many factors: lack of sleep, physical inertia, poorly balanced diet, obesity, heart disease. The fast pace of life forces a person to be in permanent stress, so as not to miss anything and have time for all the goals. This is why there is a demand for excipients and substances that could improve the peak of human cognitive abilities, maintain psychological stability. Today, the pharmaceutical market offers drugs that, according to pharmaceutical marketers, have solutions to the problems outlined above. These substances are classified to group of nootropic drugs (racetams). Objective. Review of high quality research on the effectiveness of nootropic drugs. Materials and methods. The literature review was performed using such scientometric databases as: PubMed, Cochrane Library, Scopus, BMJ Evidence-Based Medicine, Ingecta, Web of Science, UpToDate. The review included studies of randomized trials, placebo-controlled randomized trials, meta-analyzes, and systematic reviews. Data meet criteria A and B of evidence-based medicine. In the absence of high quality studies, studies with a lower level of evidence were selected. The search was made by topics: improving of cognitive functions, improving ability to work, improving sleep, improving mood, treatment of mental and psychiatric pathologies (Alzheimer's disease, dementia with various etiologies, depression), application in pediatrics. Results. The literature review included more than 40 high quality studies, but no conclusive evidence was found on the effectiveness of any drug. Conclusions. Data on the undeniable efficacy in relation to the cognitive functions of any of these nootropic drugs were not found in any study. In the treatment of Alzheimer's disease, some (Cerebrolysin, Nicergoline) drugs show controversial results of efficacy and safety. They require continued clinical research and they need to be approved by the FDA.

Sign in / Sign up

Export Citation Format

Share Document